Compare Repligen Corporation Common Stock (RGEN) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs 10X Genomics Inc — how do they compare? Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B), while 10X Genomics Inc trades at $69.94 (market cap $9.53B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and 10X Genomics Inc for 91 Days on average.
| RGEN | TXG | |
|---|---|---|
Market Cap | $11.31B | $9.53B |
Volume | 1,216,919 | 4,138,224 |
Sector | Health | Health |
52-Week High | $194.57 | $97.74 |
52-Week Low | $102.87 | $11.83 |
Typical Hold Time | 0 Days | 91 Days |
Enterprise Value | $11.20B | $9.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TXG (10x Genomics) trades at $71.79, down 4.52% on the day, amid a bearish technical signal. The company shows improving fundamentals with a significant reduction in net losses (-$43.54M in 2025 vs. -$183M in 2024) and positive operating cash flow of $136.05M. Recent news highlights strong demand for its new Atera spatial biology platform and a patent victory. However, valuation metrics remain elevated with a P/S of 14.86 and EV/EBITDA of 230.71.
The outlook is cautiously optimistic. Analyst consensus is mixed with a $83.30 price target implying 16% upside, but execution on Atera commercialization and sustained margin improvement are critical. Key risks include high valuation, competitive pressures, and reliance on instrument sales growth. The stock offers growth exposure to spatial biology but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
